EP Wealth Advisors LLC Buys 12,090 Shares of Zoetis Inc. (NYSE:ZTS)

EP Wealth Advisors LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 242,602 shares of the company’s stock after acquiring an additional 12,090 shares during the period. EP Wealth Advisors LLC owned 0.05% of Zoetis worth $47,399,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new stake in Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services bought a new position in Zoetis in the 3rd quarter worth about $33,000. Capital Performance Advisors LLP purchased a new position in Zoetis during the 3rd quarter valued at about $33,000. Quarry LP increased its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares during the period. Finally, Fortitude Family Office LLC lifted its holdings in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on ZTS shares. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Eleven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and an average price target of $220.80.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $176.46 on Friday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The stock has a market cap of $79.61 billion, a PE ratio of 33.17, a PEG ratio of 2.86 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company’s fifty day moving average is $182.43 and its 200 day moving average is $180.93.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. During the same quarter last year, the firm posted $1.36 earnings per share. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Research analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st were paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date was Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.